BLINCYTO

Indicated For

CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL), minimal residual disease (MRD)

About This Medication

# Amgen Safety Net Foundation Patient Guide: How to Get BLINCYTO (blinatumomab) at Low or No Cost BLINCYTO (blinatumomab) is a prescription immunotherapy used to treat certain types of acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. The **Amgen Safety Net Foundation** helps eligible uninsured or underinsured patients in the US and Puerto Rico get **BLINCYTO** for free if they meet financial need and other requirements.[1] ## About BLINCYTO **BLINCYTO** is an injectable medicine given continuously via a portable pump over 28-day cycles, with a 2-week break between cycles. It works by helping your immune system target and kill leukemia cells. It's FDA-approved for adults and children with relapsed or refractory B-cell precursor ALL, and certain minimal residual disease (MRD)-positive cases. Always follow your doctor's instructions, as treatment requires close monitoring in a medical facility for side effects like fever, low blood counts, or neurological issues. ## Who Qualifies? The program is **needs-based** for patients who can't afford their medicine. Key requirements include: - **Residency**: US or Puerto Rico resident. - **Financial need**: Demonstrate inability to pay, based on household income and resources. - **Insurance status**: Uninsured, underinsured, or Medicare Part D patients whose plan excludes BLINCYTO or where out-of-pocket costs are unaffordable.[1] **Important exclusions**: - Not eligible if enrolled in Medicaid or Medicare's Low-Income Subsidy (Extra Help).[1] - Must satisfy payer guidelines, like prior authorizations, before applying.[1] ## Income Eligibility Specific income thresholds (e.g., Federal Poverty Level percentages) are **not publicly detailed**; eligibility is determined case-by-case based on financial hardship.[1] Contact the program for a screening. Here's a general overview: | Household Size | Typical Threshold Example (if FPL-based, varies) | Notes | |---------------|------------------------------------------------|-------| | Individual | Not specified; needs-based review | Proof of income required | | Couple | Not specified; needs-based review | Household income assessed | | Family of 3 | Not specified; needs-based review | Includes all dependents | | Family of 4+ | Not specified; needs-based review | Full financial picture reviewed | **Notes**: No fixed FPL limit listed; program emphasizes generous guidelines for rare drugs like BLINCYTO.[1] Provide tax returns, pay stubs, or bank statements during screening. ## Insurance Requirements - **Uninsured**: Fully eligible if financially needy. - **Underinsured**: Including Medicare Part D, if insurance excludes BLINCYTO, generic/biosimilar unavailable, or copays unaffordable. - **Medicare patients**: Must prove inability to afford costs, not qualify for Extra Help, meet prior auth requirements, and have no other aid options.[1] - **No coverage required**, but insured patients may need to exhaust benefits first.[1] ## Step-by-Step Application Process 1. **Call for Screening**: Contact **Amgen Assist** at **(866) 264-2778** (Mon-Fri, 9 a.m.–8 p.m. ET) to check eligibility. New applicants start here.[1] 2. **Complete Patient Application**: Fill out pages 1-4 with personal info, household income, insurance details, and proof of financial need.[2] 3. **Get Physician Prescription**: Have your doctor complete page 5, including diagnosis and dosing for BLINCYTO.[2] 4. **Gather Documents**: - Proof of financial need (e.g., income statements, bills). - Valid prescription. - Proof of US/Puerto Rico residency (e.g., ID, utility bill). - Insurance status docs (e.g., denial letter, coverage summary).[1][2] 5. **Submit**: Fax to **1-833-959-1409** or follow phone instructions. Alternatively, call **1-800-932-3060** for help.[2] Keep copies! 6. **Wait for Approval**: If approved, medication ships free. **Reauthorization**: Yes, required. Currently enrolled patients get HCP notifications for renewal; must re-prove eligibility.[1] ## Timeline and Delivery - **Processing time**: Not specified; call for updates post-submission. - **Delivery**: Shipped free to your home or doctor's office.[1] - Expect initial review within days to weeks; reauth similar. ## If Denied or Alternatives - **Denied?** Ask for reasons (e.g., income too high, insurance issues). Appeal or reapply with more docs. Explore other aid like state programs, nonprofits (e.g., Patient Access Network), or generic options (none for BLINCYTO currently). - **No biosimilars** available.[1] - **Other Amgen programs** or general PAPs may help. ## Disclaimer This guide is for informational purposes based on available sources as of 2026.[1][2] Eligibility, terms, and contacts can change—**always verify directly with Amgen Safety Net Foundation at (866) 264-2778**. Not medical or legal advice. Consult your doctor for treatment decisions. Program not for patients with other coverage options.

Program information last verified: March 30, 2026